About

Achyut K Bhattacharyya, MD, is a Professor of Pathology (Clinical Scholar Track) and Clinical Surgery at the University of Arizona. His educational background includes an MBBS from Calcutta National Medical College, with internships and fellowships in general surgery and anatomic and pediatric pathology. He has extensive experience in anatomic pathology, having trained at New England Deaconess Hospital and Worcester Memorial Hospital. Dr. Bhattacharyya has received multiple awards for excellence in teaching, including Outstanding Teacher in Basic Sciences and Basic Science Educator of the Year at the University of Arizona, as well as the John R Davis Outstanding Residency Teaching Award. His research interests focus on the epidemiology of colorectal malignancy and translational medicine in colorectal cancer. He has contributed to the understanding of gastrointestinal diseases, including graft-versus-host disease with cytomegalovirus infection, the effects of dietary bile acids on colon adenomas, and the use of telepathology and virtual microscopy in telehealth. Dr. Bhattacharyya's work emphasizes both clinical pathology and innovative diagnostic techniques, supporting his role as a dedicated educator and researcher in the field of pathology.

Research topics

• Medicine
• Oncology
• Pathology
• Internal medicine
• Genetics
• Biology
• Intensive care medicine
• Physical therapy
• Nursing
• Anatomy
• Cancer research
• Psychiatry

Selected publications

• 141P Soft tissue sarcoma: A real-world analysis in a tertiary care centre from Northeast India

  ESMO Open · 2025-03-01

  articleOpen access

  Soft tissue sarcomas (STSs), accounting for ∼1% of all cancers, encompass a heterogeneous group of histopathological subtypes. Outcomes are notably improved following complete surgical resection, with perioperative radiotherapy and/or chemotherapy enhancing disease-free survival (DFS) and overall survival (OS). Despite these advancements, the 5-year survival probability remains around 50%. Advanced STSs demonstrate poor chemotherapy response, with short progression-free survival and OS typically <2 years.

  PublisherOA PDFDOI

• Supplementary Figure 2 from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  2023

  • Internal medicine
  • Medicine
  • Oncology

  Supplementary Figure 2 from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  PublisherDOI

• Supplementary Table 3 from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  2023-03-30

  supplementary-materialsOpen access

  Supplementary Table 3 from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  PublisherOA PDFDOI

• Supplementary Table 3 from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  2023-03-30

  supplementary-materialsOpen access

  Supplementary Table 3 from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  PublisherDOI

• Supplementary Figure 1 from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  2023-03-30

  preprintOpen access

  Supplementary Figure 1 from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  PublisherOA PDFDOI

• Supplementary Table 1 from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  2023-03-30

  supplementary-materialsOpen access

  Supplementary Table 1 from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  PublisherDOI

• Supplementary Figure Legends 1-2 from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  2023-03-30

  preprintOpen access

  Supplementary Figure Legends 1-2 from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  PublisherDOI

• Supplementary Figure 2 from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  2023-03-30

  preprintOpen access

  Supplementary Figure 2 from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  PublisherOA PDFDOI

• Supplementary Figure Legends 1-2 from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  2023-03-30

  preprintOpen access

  Supplementary Figure Legends 1-2 from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  PublisherOA PDFDOI

• Data from A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

  2023-03-30

  preprintOpen access

  &lt;div&gt;Abstract&lt;p&gt;Esophageal adenocarcinoma risk in Barrett's esophagus (BE) is increased 30- to 125-fold versus the general population. Among all BE patients, however, neoplastic progression occurs only once per 200 patient-years. Molecular biomarkers are therefore needed to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression. We therefore performed a retrospective, multicenter, double-blinded validation study of eight BE progression prediction methylation biomarkers. Progression or nonprogression were determined at 2 years (tier 1) and 4 years (tier 2). Methylation was assayed in 145 nonprogressors and 50 progressors using real-time quantitative methylation-specific PCR. Progressors were significantly older than nonprogressors (70.6 versus 62.5 years; &lt;i&gt;P&lt;/i&gt; &lt; 0.001). We evaluated a linear combination of the eight markers, using coefficients from a multivariate logistic regression analysis. Areas under the ROC curve (AUC) were high in the 2-year, 4-year, and combined data models (0.843, 0.829, and 0.840; &lt;i&gt;P&lt;/i&gt; &lt; 0.001, &lt;0.001, and &lt;0.001, respectively). In addition, even after rigorous overfitting correction, the incremental AUCs contributed by panels based on the 8 markers plus age versus age alone were substantial (Δ-AUC = 0.152, 0.114, and 0.118, respectively) in all 3 models. A methylation biomarker–based panel to predict neoplastic progression in BE has potential clinical value in improving both the efficiency of surveillance endoscopy and the early detection of neoplasia. [Cancer Res 2009;69(10):4112–5]&lt;/p&gt;&lt;/div&gt;

  PublisherDOI

Frequent coauthors

• Ronald S. Weinstein

  39 shared

• Anna R. Graham

  Barts Health NHS Trust

  29 shared

• Elizabeth A. Krupinski

  Emory University

  25 shared

• Mark A. Nelson

  University of Arizona

  25 shared

• Richard E. Sampliner

  23 shared

• Lynne Richter

  University of Arizona

  23 shared

• Katherine Scott

  22 shared

• John R. Davis

  Healthwise

  21 shared

Awards & honors

• Outstanding Teacher in Basic Sciences, University of Arizona…
• Outstanding Teacher in Basic Science, University of Arizona-…
• Dean's Award for Excellence in Teaching, University of Arizo…
• Dean's Award for Excellence in Teaching, University of Arizo…
• Basic Science Educator of the Year, University of Arizona-20…